Cargando…
Antimalarials – old drugs are new again
The aim of this study was to discuss the therapeutic mechanism of action of antimalarials, in particular hydroxychloroquine (HCQ), in patients with lupus erythematosus. It examines the results of recent studies indicating the need to revise the indications, dosage and duration of safe therapy, thus...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131958/ https://www.ncbi.nlm.nih.gov/pubmed/35645661 http://dx.doi.org/10.5114/ada.2021.108423 |
_version_ | 1784713282040365056 |
---|---|
author | Woźniacka, Anna |
author_facet | Woźniacka, Anna |
author_sort | Woźniacka, Anna |
collection | PubMed |
description | The aim of this study was to discuss the therapeutic mechanism of action of antimalarials, in particular hydroxychloroquine (HCQ), in patients with lupus erythematosus. It examines the results of recent studies indicating the need to revise the indications, dosage and duration of safe therapy, thus limiting the possibility of adverse effects. Historically, HCQ was recommended for patients with arthritis as a predominant symptom, whereas today, it is recommended for all lupus patients, even those with lupus nephritis and pregnant women; it has a favourable therapeutic profile, particularly regarding its effect on the activity of the disease, and the possibility of prolonging survival time and preventing organ damage and dysfunction. Antimalarials are basic, disease-modifying antirheumatic drugs, which not only relieve the symptoms of inflammation, but also affect the underlying processes; therefore, they should be administered chronically, and the expected effects may sometimes take a long time to become apparent. In the past, the recommended dose was 6.5 mg/kg ideal body weight, whereas today it is up to 5.0 mg/kg real body weight. A very important aspect of long-term therapy is the strict adherence to the medical prescription; hence, the introduction of a new formulation containing 400 mg of hydroxychloroquine sulphate per tablet is an interesting proposal. |
format | Online Article Text |
id | pubmed-9131958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-91319582022-05-26 Antimalarials – old drugs are new again Woźniacka, Anna Postepy Dermatol Alergol Review Paper The aim of this study was to discuss the therapeutic mechanism of action of antimalarials, in particular hydroxychloroquine (HCQ), in patients with lupus erythematosus. It examines the results of recent studies indicating the need to revise the indications, dosage and duration of safe therapy, thus limiting the possibility of adverse effects. Historically, HCQ was recommended for patients with arthritis as a predominant symptom, whereas today, it is recommended for all lupus patients, even those with lupus nephritis and pregnant women; it has a favourable therapeutic profile, particularly regarding its effect on the activity of the disease, and the possibility of prolonging survival time and preventing organ damage and dysfunction. Antimalarials are basic, disease-modifying antirheumatic drugs, which not only relieve the symptoms of inflammation, but also affect the underlying processes; therefore, they should be administered chronically, and the expected effects may sometimes take a long time to become apparent. In the past, the recommended dose was 6.5 mg/kg ideal body weight, whereas today it is up to 5.0 mg/kg real body weight. A very important aspect of long-term therapy is the strict adherence to the medical prescription; hence, the introduction of a new formulation containing 400 mg of hydroxychloroquine sulphate per tablet is an interesting proposal. Termedia Publishing House 2021-08-11 2022-04 /pmc/articles/PMC9131958/ /pubmed/35645661 http://dx.doi.org/10.5114/ada.2021.108423 Text en Copyright: © 2022 Termedia Sp. z o. o. https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Review Paper Woźniacka, Anna Antimalarials – old drugs are new again |
title | Antimalarials – old drugs are new again |
title_full | Antimalarials – old drugs are new again |
title_fullStr | Antimalarials – old drugs are new again |
title_full_unstemmed | Antimalarials – old drugs are new again |
title_short | Antimalarials – old drugs are new again |
title_sort | antimalarials – old drugs are new again |
topic | Review Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131958/ https://www.ncbi.nlm.nih.gov/pubmed/35645661 http://dx.doi.org/10.5114/ada.2021.108423 |
work_keys_str_mv | AT wozniackaanna antimalarialsolddrugsarenewagain |